Nothing Special   »   [go: up one dir, main page]

Farr et al., 2014 - Google Patents

Phage-based nanomaterials for biomedical applications

Farr et al., 2014

Document ID
17169095560240762404
Author
Farr R
Choi D
Lee S
Publication year
Publication venue
Acta biomaterialia

External Links

Snippet

Recent advances in nanotechnology enable us to manipulate and produce materials with molecular level control. In the newly emerging field of bionanomedicine, it is essential to precisely control the physical, chemical and biological properties of materials. Among other …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Bacteriophages
    • C12N2795/10011—Bacteriophages dsDNA Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Bacteriophages
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48776—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form forms of ingredients not provided for by groups A61K47/48784 - A61K47/48992, e.g. cells, cell fragments, viruses, ghosts, red blood cells, viral vectors having the pharmacologically or therapeutically active agent complexed or covalently linked to, or being themselves modified by complexation or covalent linkage by a modifying agent

Similar Documents

Publication Publication Date Title
Farr et al. Phage-based nanomaterials for biomedical applications
Karimi et al. Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos
Sunderland et al. Phage‐enabled nanomedicine: from probes to therapeutics in precision medicine
Huh et al. Bacteriophage interactions with mammalian tissue: Therapeutic applications
Eiben et al. Plant virus-based materials for biomedical applications: Trends and prospects
Ling et al. Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era
Giessen Encapsulins: microbial nanocompartments with applications in biomedicine, nanobiotechnology and materials science
Henry et al. Tools from viruses: bacteriophage successes and beyond
Schwarz et al. Biomedical and catalytic opportunities of virus-like particles in nanotechnology
Wen et al. Design of virus-based nanomaterials for medicine, biotechnology, and energy
Chang et al. Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: From tissue regeneration to cancer therapy
Sokullu et al. Plant/bacterial virus-based drug discovery, drug delivery, and therapeutics
Leal et al. Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery
Carmody et al. Bacteriophage capsid modification by genetic and chemical methods
Stephanopoulos Strategies for stabilizing DNA nanostructures to biological conditions
Bakhshinejad et al. Bacteriophages and medical oncology: targeted gene therapy of cancer
Jiang et al. Exploring phage engineering to advance nanobiotechnology
El-Gazzar et al. Advances in phage inspired nanoscience based therapy
Galloway et al. Bioinspired silicification reveals structural detail in self-assembled peptide cages
Merabishvili et al. Production of phage therapeutics and formulations: Innovative approaches
JP2009502132A (en) Membrane translocation peptide
WO2009120895A2 (en) Recombinant bacteriophages useful for tissue engineering
Bakhshinejad et al. Bacteriophages and development of nanomaterials for neural regeneration
Kumar et al. Phage for drug delivery vehicles
Karimi et al. Aptamers and pathogen-based carriers